首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 2019年 10期HBV感染“新型”生物标志物的临床应用 => 肝脏肿瘤 =>微波消融联合经肝动脉..
微波消融联合经肝动脉化疗栓塞术治疗原发性肝癌合并门静脉癌栓的效果及影响因素
Clinical effect of microwave ablation combined with transcatheter arterial chemoembolization in treatment of primary hepatocellular carcinoma with portal vein tumor thrombus and related influencing factors
文章发布日期:2019年09月05日  来源:  作者:周传力,田世超,陈晓理, 等  点击次数:145次  下载次数:20次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】: 目的 探讨微波消融(MWA)联合经肝动脉化疗栓塞术(TACE)治疗原发性肝癌(PHC)合并门静脉癌栓(PVTT)的效果及主要影响因素。方法 选取2016年1月-2018年3月成都市第七人民医院收治的PHC合并PVTT患者92例,其中接受MWA联合TACE治疗的患者为联合组(n=47),仅接受TACE治疗的为对照组(n=45)。观察2组患者治疗后短期疗效、生存情况、不良反应、并发症发生率,以及完全缓解(CR)、部分缓解(PR)、疾病稳定(SD)和疾病进展(PD);比较2组患者术后3个月治疗有效率(RR)。计量资料2组间比较采用t检验,计数资料2组间比较采用χ2检验。用Kaplan-Meier法进行生存分析,log-rank检验对各项可能因素进行单因素分析,用Cox逐步回归方法进行多因素分析。结果 治疗结束后3个月,联合组和对照组RR分别为42.2%和11.9%,差异有统计学意义(χ2=8.679,P<0.05)。2组患者治疗后3 d均出现发热、恶心呕吐和肝区疼痛等不良反应。联合组患者1、2、3年累积生存率分别为44.7%、23.4%、6.4%,对照组患者1、2、3年累积生存率分别为22.5%、8.9%、0,联合组中位生存时间(10.9个月)明显高于对照组(5.1个月),差异有统计学意义(χ2=5.749,P<0.05)。术前AFP、肿瘤数目、肿瘤大小、癌栓分型、BCLC分期和Child-Pugh分级与合并PVTT 的PHC患者的生存相关(χ2值分别为9.356、7.641、11.352、9.764、8.236、17.392,P值均<0.05)。多因素分析显示,肿瘤大小、癌栓分型、BCLC分期是影响患者生存的独立因素[风险比 (95%可信区间)分别为1.997 (1.608~3.145)、1.584 (1.306~2.757)、1.690 (1.035~2.683),P值均<0.05]。结论 MWA联合TACE治疗PHC合并PVTT具有更好的安全性和有效性,影响患者预后的主要因素是肿瘤大小、癌栓分型、BCLC分期。
【Abstract】: Objective To investigate the clinical effect of microwave ablation (MWA) combined with transcatheter arterial chemoembolization (TACE) in the treatment of primary hepatocellular carcinoma (PHC) with portal vein tumor thrombus (PVTT) and related influencing factors. Methods A total of 92 patients with PHC and PVTT who were admitted to Chengdu Seventh People’s Hospital from January 2016 to March 2018 were enrolled, among whom 47 patients treated with MWA combined with TACE were enrolled as combined treatment group and 45 treated with TACE alone were enrolled as control group. The two groups were compared in terms of short-term outcome, survival, incidence rates of adverse reactions and complications, and rates of complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD), as well as response rate (RR) at 3 months after surgery (RR=CR+PR). The t-test was used for comparison of continuous data between groups, and the chi-square test was used for comparison of categorical data between groups. The Kaplan-Meier method was used for survival analysis, the log-rank test was used for univariate analysis of possible factors, and a Cox stepwise regression analysis was used for multivariate analysis. Results At 3 months after the treatment ended, there was a significant difference in RR between the combined treatment group and the control group (42.2% vs 11.9%, χ2=8.679, P<0.05). The adverse reactions such as pyrexia, nausea and vomiting, and liver area pain were observed in both groups. The combined treatment group had 1-, 2-, and 3-year cumulative survival rates of 44.7%, 23.4%, and 6.4%, respectively, and the control group had 1-, 2-, and 3-year cumulative survival rates of 22.5%, 8.9%, and 0, respectively. The combined treatment group had a significantly longer median survival time than the control group (10.9 months vs 5.1 months, χ2=5.749, P<0.05). Preoperative alpha-fetoprotein, number of tumors, tumor size, type of PVTT, Barcelona Clinic Liver Cancer (BCLC) stage, and Child-Pugh class were associated with the survival of the patients with PHC and PVTT (χ2=9.356, 7.641, 11.352, 9.764, 8.236, and 17.392, all P<0.05). The multivariate analysis showed that tumor size (hazard ratio[HR]=1.997, 95% confidence interval [CI]: 1.608-3.145, P<0.05), type of PVTT (HR=1.584,95%CI:1.306-2.757, P<0.05), BCLC stage (HR=1.690,95%CI:1.035-2.683, P<0.05) were independent influencing factors for survival. Conclusion MWA combined with TACE has good safety and efficacy in the treatment of patients with PHC and PVTT. Tumor size, type of PVTT, BCLC stage are the main influencing factors for prognosis.
【关键字】:肝肿瘤; 消融技术; 经肝动脉化疗栓塞术; 危险因素
【Key words】:liver neoplasms; ablation techniques; transcatheter arterial chemoembolization; risk factors
【引证本文】:ZHOU CL, TIAN SC, CHEN XL, et al. Clinical effect of microwave ablation combined with transcatheter arterial chemoembolization in treatment of primary hepatocellular carcinoma with portal vein tumor thrombus and related influencing factors[J]. J Clin Hepatol, 2019, 35(10): 2220-2224. (in Chinese)
周传力, 田世超, 陈晓理, 等. 微波消融联合经肝动脉化疗栓塞术治疗原发性肝癌合并门静脉癌栓的效果及影响因素[J]. 临床肝胆病杂志, 2019, 35(10): 2220-2224.

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号